Advanced diagnostic support in lipidology project: Role for phenotypic and functional evaluation of lipoproteins in dyslipidemias

Clinical Lipidology

Volumn 5, Issue 3, 2010, Pages 329-337

  Ardig D ^a   Bernini, F ^b   Borghi, C ^c   Calandra, S ^d   Cicero, Afg ^c   Favari, E ^b   Fellin, R ^e   Franzini, L ^a   Vigna, Gb ^e   Zimetti, F ^b   Zavaroni, I ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e Azienda Ospedaliero Universitaria di Ferrara ^*  (Italy)

Author keywords

dyslipidemia; intima media thickness; lipoprotein; reverse cholesterol transport; small dense LDL

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL RESEARCH; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVIEW; RISK FACTOR;

EID: 77953814703     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.20     Document Type: Review

References (46)

1. Lusis AJ: Atherosclerosis. Nature 407, 233-241 (2000).
2. Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
3. Norata GD, Raselli S, Grigore L et al.: Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Atherosclerosis 206(2), 556-562 (2009).
4. Rye KA, Bursill CA, Lambert G et al.: The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50(Suppl.), S195-S200 (2009).
5. Gordon DJ, Probstfield JL, Garrison RJ et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8-15 (1989).
6. Ritz E, Wanner C: Lipid abnormalities and cardiovascular risk in renal disease. J. Am. Soc. Nephrol. 19, 1065-1070 (2008).
7. Soutar AK, Naoumova RP: Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Card. Vasc. Med. 4, 214-225 (2007).
8. Souverein OW, Defesche JC, Zwinderman AH et al.: Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolemia. Eur. Heart J. 28, 299-304 (2007).
9. Dastani Z, Engert J, Genest J, Marcil M: Genetics of high density lipoproteins. Curr. Opin. Lipidol. 21, 329-335 (2006).
10. Kees Hovingh G, de Groot E, Van Der Steeg W et al. Inherited disorders of HDL metabolism and atherosclerosis Curr. Opin. Lipidol. 16, 139-145 (2005).
11. Rizzo M, Berneis K: Low-density lipoprotein size and cardiovascular risk assessment. QJM 99, 1-14 (2006). (Pubitemid 43124966)
12. Fraley AE, Tsimikas S: Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr. Opin. Lipidol. 17, 502-509 (2006).
13. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL - guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med. 3, 144-153 (2006).
14. Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96, 1221-1232 (2005).
15. Yancey PG, Bortnick AE, Kellner-Weibel G et al.: Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 23, 712-719 (2003).
16. De La Llera-Moya M, Connelly MA, Drazul D et al.: Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. J. Lipid Res. 42, 1969-1978 (2001).
17. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42, 1007-1017 (2001). (Pubitemid 32645780)
18. Yancey PG, de la Llera-Moya M, Swarnakar S et al.: High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 275, 36596-36604 (2000).
19. Favari E, Lee M, Calabresi L et al.: Depletion of pre-b-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J. Biol. Chem. 279, 9930-9936 (2004).
20. Favari E, Calabresi L, Adorni MP et al.: Small discoidal pre-b1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48, 11067-11074 (2009).
21. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ: Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 115, 2870-2874 (2005).
22. Calabresi L, Favari E, Moleri E et al.: Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis 204, 141-146 (2009).
23. Favari E, Gomaraschi M, Zanotti I et al.: A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding cassette A1-mediated cell cholesterol efflux. J. Biol. Chem. 282, 5125-5132 (2007).
24. Marks D, Thorogood M, Neil HAW, Humphries SE: A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168, 1-14 (2003).
25. Bertolini S, Simone ML, Pes GM et al.: Pseudodominance of lipoprotein lipase (LPL) deficiency due to a nonsense mutation (Tyr302>Term) in exon 6 of LPL gene in an Italian family from Sardinia (LPLOlbia). Clin. Genet. 57, 140-147 (2000).
26. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH: Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305, 869-872 (2004).
27. Perez-Mendez O, Duhal N, Lacroix B, Bonte JP, Fruchart JC, Luc G: Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene. Clin. Chim. Acta 368, 149-154 (2006).
28. Pisciotta L, Priore Oliva C, Cefalù AB et al.: Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 186, 433-440 (2006).
29. Di Leo E, Magnolo L, Pinotti E et al.: Functional analysis of two novel splice site mutations of APOB gene in familial hypobetalipoproteinemia. Mol. Genet. Metab. 96, 66-72 (2009).
30. Rabacchi C, Wunsh A, Ghisellini M et al.: An apparent inconsistency in parent to offspring transmission of point mutations of LDLR gene in familial hypercholesterolemia. Clin. Chim. Acta 406, 75-80 (2009).
31. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 32, S62-S67 (2009).
32. Snyder S, Pendergraph B: Detection and evaluation of chronic kidney disease. Am. Fam. Physician. 72(9), 1723-1732 (2005).
33. Cicero AF, Manca M, Bove M et al.; Brisighella Heart Study Group: Detection of familial combined hyperlipoproteinaemia patients in the Brisighella Heart Study historical cohort: an epidemiological approach. J. Inherit. Metab. Dis. 30(2), 268 (2007).
34. Cicero AF, Dormi A, Nascetti S et al.: Relative role of major risk factors for Type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabet. Med. 22(9), 1263-1266 (2005).
35. Hoefner DM, Hodel SD, O'Brien JF et al.: Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin. Chem. 47, 266-274 (2001).
36. Gentile M, Panico S, Jossa F et al.: Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Atena. Clin. Chim. Acta 388, 179-183 (2008).
37. Chung BH, Segrest JP, Ray MJ et al.: Single vertical spin density gradient ultracentrifugation. Meth. Enzymol. 128, 181-209 (1986).
38. Esterbauer, H, Striegl G, Puhl H, Rotheneder M: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res. Commun. 6, 67-75 (1989).
39. Duong M, Collins HL, Jin W et al.: Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arterioscler. Thromb. Vasc. Biol. 26, 541-547 (2006).
40. Franceschini G, Calabresi L, Colombo C et al.: Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 195, 385-391 (2007).
41. Tanigawa H, Billheimer JT, Tohyama J et al.: Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 120, 160-169 (2009).
42. O'Leary DH, Polak JF, Kronmal RA et al.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340, 14-22 (1999).
43. Redberg RF, Vogel RA, Criqui MH et al.: Task Force #3 - what is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J. Am. Coll. Cardiol. 41, 1886-1898 (2003).
44. Simon A, Megnien JL, Chironi G: The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 30(2), 182-185 (2010).
45. Tardif JC, Heinonen T, Orloff D, Libby P: Vascular biomarkers and surrogates in cardiovascular disease. Circulation 113(25), 2936-2942 (2006).
46. Simon A, Chironi G, Levenson J: Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Eur. Heart J. 28(24), 2967-2971 (2007).